Makiko Tajika
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Makiko Tajika has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Akira Ohtake
Affiliations Department of Pediatrics, Saitama Medical University Hospital, Moroyama, Japan, Department of Clinical Genomics, Saitama Medical University Hospital, Moroyama, Japan
1 shared publication - Atsuko Imai-Okazaki
Department of Diagnostics and Therapeutics of Intractable Diseases, Juntendo University Graduate School of Medicine, Tokyo, Japan.
1 shared publication - Ayako Matsunaga
Center for Medical Genetics, Chiba Children’s Hospital, Chiba City, Japan
1 shared publication Hideo Sugie
Faculty of Health and Medical Sciences, Tokoha University, Hamamatsu, Shizuoka, Japan
1 shared publication- Hideshi Tomita
Cardiovascular Center, Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan
1 shared publication - Ichizo Nishino
Department of Neuromuscular Research National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP) Tokyo Japan
1 shared publication
Latest Publications
- Open Access
- 7 October 2021
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 107 (3) , 329-334
Neonatal-onset mitochondrial disease: clinical features, molecular diagnosis and prognosis
Objective Neonatal-onset mitochondrial disease has not been fully characterised owing to its heterogeneity. We analysed neonatal-onset mitochondrial disease in Japan to clarify its clinical features, molecular diagnosis and prognosis. Design Retrospective observational study from January 2004 to March 2020. Setting Population based. Patients Patients (281) with neonatal-onset mitochondrial disease diagnosed by biochemical and genetic approaches. Interventions None. Main outcome measures Disease types, initial symptoms, biochemical findings, molecular diagnosis and prognosis. Results Of the 281 patients, multisystem mitochondrial disease was found in 194, Leigh syndrome in 26, cardiomyopathy in 38 and hepatopathy in 23 patients. Of the 321 initial symptoms, 236 occurred within 2 days of birth. Using biochemical approaches, 182 patients were diagnosed by mitochondrial respiratory chain enzyme activity rate and 89 by oxygen consumption rate. The remaining 10 patients were diagnosed using a genetic approach. Genetic analysis revealed 69 patients had nuclear DNA variants in 36 genes, 11 of 15 patients had mitochondrial DNA variants in five genes and four patients had single large deletion. The Cox proportional hazards regression analysis showed the effects of Leigh syndrome (HR=0.15, 95% CI 0.04 to 0.63, p=0.010) and molecular diagnosis (HR=1.87, 95% CI 1.18 to 2.96, p=0.008) on survival. Conclusions Neonatal-onset mitochondrial disease has a heterogenous aetiology. The number of diagnoses can be increased, and clarity regarding prognosis can be achieved by comprehensive biochemical and molecular analyses using appropriate tissue samples.
- 7 October 2021
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
- Vol. 107 (3) , 329-334
Open AccessNeonatal-onset mitochondrial disease: clinical features, molecular diagnosis and prognosis
Objective Neonatal-onset mitochondrial disease has not been fully characterised owing to its heterogeneity. We analysed neonatal-onset mitochondrial disease in Japan to clarify its clinical features, molecular diagnosis and prognosis. Design Retrospective observational study from January 2004 to March 2020. Setting Population based. Patients Patients (281) with neonatal-onset mitochondrial disease diagnosed by biochemical and genetic approaches. Interventions None. Main outcome measures Disease types, initial symptoms, biochemical findings, molecular diagnosis and prognosis. Results Of the 281 patients, multisystem mitochondrial disease was found in 194, Leigh syndrome in 26, cardiomyopathy in 38 and hepatopathy in 23 patients. Of the 321 initial symptoms, 236 occurred within 2 days of birth. Using biochemical approaches, 182 patients were diagnosed by mitochondrial respiratory chain enzyme activity rate and 89 by oxygen consumption rate. The remaining 10 patients were diagnosed using a genetic approach. Genetic analysis revealed 69 patients had nuclear DNA variants in 36 genes, 11 of 15 patients had mitochondrial DNA variants in five genes and four patients had single large deletion. The Cox proportional hazards regression analysis showed the effects of Leigh syndrome (HR=0.15, 95% CI 0.04 to 0.63, p=0.010) and molecular diagnosis (HR=1.87, 95% CI 1.18 to 2.96, p=0.008) on survival. Conclusions Neonatal-onset mitochondrial disease has a heterogenous aetiology. The number of diagnoses can be increased, and clarity regarding prognosis can be achieved by comprehensive biochemical and molecular analyses using appropriate tissue samples.
- Open Access
- 1 December 2016
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 9, 98-105
Divergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state
- 1 December 2016
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 9, 98-105
Open AccessDivergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state